Full cohort N (%) | PDL1 known group N (%) | |
Age | ||
≥65 | 92 (57) | 70 (61) |
<65 | 69 (43) | 44 (39) |
Sex | ||
M | 90 (56) | 66 (58) |
F | 71 (44) | 48 (42) |
ECOG | ||
≤1 | 137 (85) | 96 (84) |
>1 | 23 (14) | 17 (15) |
Unknown | 2 (1) | 1 (1) |
Smoking | ||
Yes | 131 (81) | 91 (80) |
No | 19 (12) | 14 (12) |
Unknown | 11 (7) | 9 (8) |
Histopathology | ||
Adenocarcinoma | 106 (66) | 74 (65) |
SCC | 45 (28) | 32 (28) |
Others | 10 (6) | 8 (7) |
Molecular status* | ||
KRAS mutant | 55 (47) | 41 (50) |
KRAS wild type | 46 (40) | 36 (44) |
KRAS unknown | 10 (9) | 2 (2) |
EGFR, ALK or ROS1 mutant | 5 (4) | 3 (4) |
Line of treatment | ||
First line | 37 (23) | 37 (32) |
Second or more | 124 (77) | 77 (68) |
Total | 161 | 114 |
*Molecular status was only examined in NSCLC with non-squamous cell carcinoma histology (116 patients in full cohort and 82 in the PDL1 known group).
ALK, echinoderm microtubule-associated protein like-4-anaplastic lymphoma kinase (EML4/ALK) fusion; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; KRAS, Kirsten Rat Sarcoma GTPase; NSCLC, non-small cell lung cancer; PDL1, programmed death ligand; ROS1, echinoderm c-ros oncogene 1 fusion; SCC, squamous cell carcinoma.